Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esaxerenone versus ARBs in older patients with uncontrolled hypertension on amlodipine
jRCTs031240300Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2024
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of esaxerenone, azilsartan, irbesartan, olmesartan, candesartan cilexetil and 3 more in hypertension (HTN) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change from baseline in morning home systolic blood pressure. Started Sep 2024; status: completed.
02
Drugs
esaxerenoneazilsartanirbesartanolmesartancandesartan cilexetil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCTs031240300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031240300.